You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Novel Technology to Disseminate WOOP (Wish, Outcome, Obstacle, Plan) to Dementia Caregivers

    SBC: BORROW MY GLASSES LLC            Topic: NIA

    1 Approximately 6.5 million Americans aged 65 and older live with dementia, supported by more than 11 million2 unpaid family caregivers. These numbers are projected to rise exponentially in the coming decades fueling the3 need to develop scalable ways to support dementia caregivers. The need to empower dementia caregivers to4 continue providing care while maintaining their own health and well-bein ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. miRNA-Nanotechnology as a novel regenerative therapy for lymphangioleiomyomatosis

    SBC: BIOSPUTNIK LLC            Topic: 172

    ABSTRACT Lymphangioleiomyomatosis (LAM) is a Tuberous sclerosis-related disorder. Both occur due to an inherited or sporadic mutation in either the TSC1 or TSC2 gene, which function as negative regulators of the mTOR pathway. Uncontrolled mTORC1 activity leads to the neoplastic proliferation of abnormal smooth muscle cells (LAM cells) in the lungs, progressive shortness of breath, recurrent pneumo ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Engineered Biotherapeutic Agent for Treatment of Post-Traumatic Osteoarthritis

    SBC: Provizigen LLC            Topic: NIAMS

    PROJECT SUMMARY/ABSTRACT Post-traumatic osteoarthritis (PTOA) is a degenerative disease of cartilage brought on by traumatic injury to the articular joints. Acute joint injury is followed by severe joint pain and inflammation. This results in much more rapid degeneration of cartilage than in other forms of osteoarthritis, due to the joint instability caused by trauma as well as the increase in pro ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. THERAPY FOR ALCOHOL USE DISORDER

    SBC: ARTIAM BIO INC.            Topic: 150

    Abstract Alcohol use disorder (AUD) is a major global health issue. In the US, AUD affects over 14 million people over the age of 18. While there are three approved drugs for AUD, less than 4% of patients eligible for pharmacotherapy are prescribed a medication – likely due to limited efficacy of currently approved agents. Also, the relapse rate for AUD continues to be exceedingly high. Thus, ne ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Improving parent-adolescent communication about sexual and reproductive health

    SBC: Teen Health Research, Inc.            Topic: NICHD

    PROJECT SUMMARY Early adolescence, between the ages of 10-13, is a critical time for sexuality development. It is a period when most young people enter puberty and have new questions about bodies, relationships, and sexual activity. However, the majority of US adolescents enter this early adolescent period without access to the kind of inclusive, comprehensive sex education that could help them de ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Urine Test for At-Home Monitoring of Blood Phe Levels for PKU

    SBC: CIRCA BIOSCIENCE LLC            Topic: NICHD

    PROJECT SUMMARY/ABSTRACT This project proposes the development of technologies to provide low-cost monitoring of phenylalanine (Phe) levels in the blood by a simple, noninvasive, at-home urine test, in order to enable daily monitoring by individuals with phenylketonuria (PKU). Also known as phenylalanine hydroxylase deficiency, PKU is a rare inborn error of metabolism that occurs in the US at a fr ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. An IGF-1R-targeting peptide drug conjugate for targeted treatment of atypical teratoid/rhabdoid tumors

    SBC: NIGHTHAWK BIOSCIENCES, INC.            Topic: 102

    PROJECT SUMMARY Atypical teratoid/rhabdoid tumors (AT/RT) are rare embryonal central nervous system malignancies that occur in early childhood and are lethal. Current treatment strategies for children diagnosed with AT/RT are limited to surgery, radiation, and chemotherapy, but to date, none of these have successfully improved survival beyond 18 months, and most are associated with significant tox ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. CRISPR-Cas Editing as a Genetic Cure for Autosomal Dominant Polycystic Kidney Disease

    SBC: NEPHROGEN INC.            Topic: 400

    PROJECT SUMMARY Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic disorder in the world and affects 650,000 Americans. ADPKD is caused by mutations in Pkd1 or Pkd2 that trigger proliferation and fluid secretion by renal tubular epithelial cells into cysts, which bilaterally enlarge the kidney and lead to progressive loss of kidney function. There is no cure for ADPK ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia

    SBC: FGF Therapeutics INC.            Topic: NIAMS

    Abstract Hyperphosphatemic familial tumoral calcinosis (hfTC) is a disease in which patients cannot produce the bioactive form of the hormone Fibroblast growth factor-23 (FGF23), which is secreted by osteocytes to rid the body of phosphate by acting on the kidney. hfTC is characterized by markedly elevated serum phosphate (Pi) which causes large intramuscular calcifications to develop. The calcifi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Addressing bone marrow lesions that compromise osteochondral tissue repair

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    ABSTRACT Degenerative joint diseases such as osteoarthritis (OA) remain the source of significant pain and disability, affecting over 30 million adults with an annual US economic burden of more than $486 billion. Joint replacement is a well-established procedure, but its finite life span makes this treatment unacceptable for younger (under 65) or more active individuals. For this growing patient p ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government